Autor segons l'article: Jara-Palomares L; Solier-Lopez A; Elias-Hernandez T; Asensio-Cruz M; Blasco-Esquivias I; Marin-Barrera L; de la Borbolla-Artacho M; Praena-Fernandez J; Montero-Romero E; Navarro-Herrero S; Serrano-Gotarredona M; Sánchez-Díaz J; Palacios C; Otero R
Departament: Medicina i Cirurgia
Autor/s de la URV: Porras Ledantes, Jose Antonio
Paraules clau: Venous thromboembolism Venous thromboembolic disease Vein thrombosis Tinzaparin Pulmonary-embolism Pulmonary embolism Prevention Practice guideline update Oral anticoagulants Molecular-weight heparin Management Low-molecular-weight heparin Cancer Antithrombotic therapy American society tinzaparin pulmonary embolism low-molecular-weight heparin cancer
Resum: © 2017 The Author(s) Introduction The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6 months are unknown. Our aim was to determine the safety of long-term tinzaparin use in patients with CAT. Methods We performed a prospective, open, single arm, multicentre study in patients with CAT receiving treatment with tinzaparin. We evaluated the rate of clinically relevant bleeding events (major and non-major clinically relevant bleeding) and venous thromboembolism (VTE) recurrence. Results A total of 247 patients were recruited, with a crude incidence of major bleeding of 4.9% (12/247). The rate of clinically relevant bleeding during months 1–6 and 7–12, was 0.9% [95% confidence interval (95% CI) 0.5 to 1.6%] and 0.6% (95% CI 0.2 to 1.4%) (p = 0.5) per patient and month, respectively. Male gender showed greater risk for clinically relevant bleeding with a hazard ratio (HR) of 2.97 (95% CI 1.01 to 8.1; p = 0.02). The incidence of VTE recurrence at months 1–6 and 7–12 was 4.5% (95% CI 2.2 to 7.8%) and 1.1% (95% CI 0.1 to 3.9%), respectively. One patient died due to VTE recurrence and two because of severe bleeding. Conclusions Treatment with tinzaparin beyond 6 months is safe in patients with CAT.
Àrees temàtiques: Saúde coletiva Química Psicología Peripheral vascular disease Medicina iii Medicina ii Medicina i Interdisciplinar Hematology General medicine Farmacia Ensino Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biodiversidade Astronomia / física
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 00493848
Adreça de correu electrònic de l'autor: joseantonio.porras@urv.cat
Identificador de l'autor: 0000-0001-6418-1822
Data d'alta del registre: 2024-09-07
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://www.sciencedirect.com/science/article/pii/S0049384817304061
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Thrombosis Research. 157 90-96
Referència de l'ítem segons les normes APA: Jara-Palomares L; Solier-Lopez A; Elias-Hernandez T; Asensio-Cruz M; Blasco-Esquivias I; Marin-Barrera L; de la Borbolla-Artacho M; Praena-Fernandez J (2017). Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. Thrombosis Research, 157(), 90-96. DOI: 10.1016/j.thromres.2017.07.004
DOI de l'article: 10.1016/j.thromres.2017.07.004
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2017
Tipus de publicació: Journal Publications